Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The transcription factor C/EBPalpha (for CCAAT/enhancer binding protein-alpha; encoded by the gene CEBPA) is crucial for the differentiation of granulocytes. Conditional expression of C/EBPalpha triggers neutrophilic differentiation, and no mature granulocytes are observed in Cebpa-mutant mice. Here we identify heterozygous mutations in CEBPA in ten patients with acute myeloid leukemia (AML). We found that five mutations in the amino terminus truncate the full-length protein, but did not affect a 30-kD protein initiated further downstream. The mutant proteins block wild-type C/EBPalpha DNA binding and transactivation of granulocyte target genes in a dominant-negative manner, and fails to induce granulocytic differentiation. Ours is the first report of CEBPA mutations in human neoplasia, and such mutations are likely to induce the differentiation block found in AML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We have recently shown mutations in the DNA-binding domain of C/EBP␣ in acute myeloid leukemia, suggesting its importance in granulocyte differentiation and leukemia.19”
From Granulocyte inducer C/EBPα inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions (2002) · cites this paper as [19]
Citations
Cites
The scanning model for translation: an update.
Kozak, M. (1989) · The Journal of cell biology · doi:10.1083/jcb.108.2.229 · Cited by 3,486 · cited 1×
“These findings support the concept that CEBPA forms detected with monospecific antibodies are alternative products translated from several in-frame initiation codons by a leaky ribosome-scanning mechanis”
BackgroundThe Leucine Zipper: A Hypothetical Structure Common to a New Class of DNA Binding Proteins
Landschulz, W. H., Johnson, P. F., & McKnight, S. L. (1988) · Science · doi:10.1126/science.3289117 · Cited by 3,443
Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.
Cao, Z., Umek, R. M., & McKnight, S. L. (1991) · Genes & Development · doi:10.1101/gad.5.9.1538 · Cited by 1,663
Chromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Descombes, P., & Schibler, U. (1991) · Cell · doi:10.1016/0092-8674(91)90531-3 · Cited by 990
Isolation of a recombinant copy of the gene encoding C/EBP.
Landschulz, W. H., Johnson, P. F., Adashi, E. Y., Graves, B. J., & McKnight, S. L. (1988) · Genes & Development · doi:10.1101/gad.2.7.786 · Cited by 956
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910 · cited 1×
“In addition, no mature granulocytes are observed in Cebpa -mutant mice, whereas all the other blood cell types are present in normal proportion”
BackgroundSelf-citationTranscription Factors, Normal Myeloid Development, and Leukemia
Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood · doi:10.1182/blood.v90.2.489 · Cited by 735 · cited 1×
“gif" NDATA ITEM> ]> Introduction A number of oncogenes that affect proliferation and cell death have been identified in leukemias and other cancers, but relatively few differentiation genes have been implicated in the malignant phenotyp”
BackgroundSelf-citationCCAAT-Enhancer Binding Protein: A Component of a Differentiation Switch
Umek, R. M., Friedman, A. D., & McKnight, S. L. (1991) · Science · doi:10.1126/science.1987644 · Cited by 712 · cited 1×
“bThe abnormalities were one del(9)(q21), one del(9)(q22q34), one t(6;9), one t(10;21)(p11;q22), one del(7)(q22q34), one +8, one +14, and four complex abnormalities.”
BackgroundRadomska, H. S., Huettner, C. S., Zhang, P., Cheng, T., Scadden, D. T., & Tenen, D. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4301 · Cited by 466 · cited 1×
“cThese patients had a 46,XY,del(12)(p11.”
Self-citation
Cited by
Items 701–800 of 930
Acute myeloid leukemia and transcription factors: role of erythroid Krüppel-like factor (EKLF)
Ayala, R. M., Martínez‐López, J., & Gilsanz, F. (2012) · Cancer Cell International · doi:10.1186/1475-2867-12-25 · Cited by 5
“The transcription factor CCAAT enhancer binding protein alpha (CEBPA) [12] is crucial for normal development of granulocytes and there is evidence that impaired CEBPA function contributes directly to the development of AML [13].”
BackgroundTranscriptional Regulation of Hematopoietic Stem Cells
Göttgens, B., & Green, A. R. (2004) · Elsevier eBooks · doi:10.1016/b978-012436643-5/50119-x · Cited by 5
Mitotic recombination in haematological malignancy
Raghavan, M., Gupta, M., Molloy, G. Y., Chaplin, T., & Young, B. D. (2009) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2009.10.030 · Cited by 5
“N terminal mutations cause deficient transactivation and are dominant negative in vitro, while C terminal mutations affect the zinc finger DNA binding domain (Pabst et al., 2001).”
BackgroundSpecificity protein-1 and -3 trans-activate the ovine placental lactogen gene promoter
Jeckel, K. M., Limesand, S. W., & Anthony, R. V. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.04.006 · Cited by 5
“1), A-CEBP (Moitra et al., 1998), generously donated by Dr. Charles Vinson (National Cancer Institute, NIH), or DN-CEBP-α (Pabst et al., 2001), a kind gift from Dr. Daniel Tenen (Harvard Medical School).”
BackgroundNature of frequent deletions in CEBPA
Fuchs, O., Kostečka, A., Provazníková, D., Krasna, B., Březinová, J., Filkuková, J., Kotlín, R., Kouba, M., Kobylka, P., Neuwirtová, R., et al. (2009) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2009.07.001 · Cited by 5
“Two or in some cases four overlapping primer pairs, which cover the entire coding region of human CEBPA, were used [11].”
MethodMolecular cytogenetic markers related to prognosis in hematological malignancies
Chen, Z. (2006) · Cited by 4
Whole-Genome/Exome Sequencing in Acute Leukemia: From Research to Clinics
Braekeleer, M. D., Braekeleer, E. D., & Douet‐Guilbert, N. (2015) · Springer eBooks · doi:10.1007/978-3-319-15811-2_22 · Cited by 4
Zhang, G., Dong, F., Luan, C., Zhang, X., Shao, H.-Y., Liu, J., & Sun, C. (2016) · Acta Haematologica · doi:10.1159/000444517 · Cited by 4
Analysis of clinical and genomic profiles of therapy-related myeloid neoplasm in Korea
Yun, J., Song, H., Kim, S., Kim, S., Kwon, S. R., Lee, Y. E., Jeong, D., Park, J. H., Kwon, S., Yun, H., et al. (2023) · Human Genomics · doi:10.1186/s40246-023-00458-8 · Cited by 4
RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia development
Carratt, S. A., Kong, G., Coblentz, C., Schonrock, Z., Maloney, L. T., Weeder, B. R., Yashar, W. M., Callahan, R. L., Blaylock, H. Z., Coleman, C., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01862-8 · Cited by 4
Prognosis and Survival in Acute Myelogenous Leukemia
Dawod, M., & Hanbali, A. S. (2012) · InTech eBooks · doi:10.5772/27092 · Cited by 5
“(Pabst et al., 2001; Fröhling et al., 2004; Foran 2010) AML-NC patients carrying a CEBPA mutation are characterized by distinct clinical features such as higher peripheral blood blast counts, lower platelet counts, less lymphadenopathy, or extramedullary leukemia.”
Genetic Alterations and Their Clinical Implications in Acute Myeloid Leukemia
Hou, H., Chou, W., & Tie, H.-F. (2011) · InTech eBooks · doi:10.5772/26421 · Cited by 5
Hikima, J.-I., Ohtani, M., Kondo, H., Hırono, I., Jung, T. S., & Aoki, T. (2010) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2010.10.003 · Cited by 4
Cytoplasmic nucleophosmin (cNPM) in acute myeloid leukaemia: Relation to disease characteristics
Kazem, A. H., Mikhael, I. L., & Ghanem, A. M. (2011) · Alexandria Journal of Medicine · doi:10.1016/j.ajme.2011.07.015 · Cited by 4
Molecular Testing in Acute Myeloid Leukemia
Behdad, A., & Betz, B. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800886-7.00033-9 · Cited by 4
Yang, M., Hsiao, H., Liu, Y., Hsu, C., Lin, S.-F., & Lin, P. (2018) · In Vivo · doi:10.21873/invivo.11137 · Cited by 4
Assaf, N., Cheikh, J. E., Bazarbachi, A. A., Salem, Z. M. K., Farra, C., Chakhachiro, Z. I., Nassif, S., Zaatari, G. S., & Mahfouz, R. A. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04649-2 · Cited by 4
Libura, M. A., Pawełczyk, M., Florek, I., Matiakowska, K., Jaźwiec, B., Borg, K., Solarska, I., Zawada, M., Czekalska, S., Libura, J., et al. (2015) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2015.07.002 · Cited by 5
Comparative proteomics in acute myeloid leukemia
Łuczak, M., Kaźmierczak, M., Hadschuh, L., Lewandowski, K. C., Komarnicki, M. A., & Figlerowicz, M. (2012) · Współczesna Onkologia · doi:10.5114/wo.2012.28787 · Cited by 4
“C/EBPα plays an important role in granulopoiesis as its dysfunction or absence leads to the inhibition of myeloid cell differentiation and, thus, to the development of leukemia [8, 9].”
BackgroundHelbig, G., Woźniczka, K., Więcławek, A., Soja, A., Bartkowska‐Chrobok, A., & Kyrcz‐Krzemień, S. (2014) · Współczesna Onkologia · doi:10.5114/wo.2014.43490 · Cited by 4
The Etiology of Acute Leukemia
Nichol, J. N., Kinal, M., & Miller, W. H. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_12 · Cited by 4
Wang, J., Xu, J., Zhang, X., Huang, Z., Liu, L., Zhang, L., Lei, X., Xue, M., Weng, J., & Long, Z. (2022) · Cell Proliferation · doi:10.1111/cpr.13331 · Cited by 4
“C/EBPα N-terminal mutations drive a dominant-negative effect on wildtype C/EBPα protein and inhibit granulocytic differentiation.(24)”
BackgroundNaik, K. A. P., Kethavath, S. N., Rosangzula, K., Saikrishna, J., Sangeetha, R., Patlolla, R. R., Chandgude, A. H., & Banoth, L. (2026) · Springer eBooks · doi:10.1007/978-981-95-5071-5_12 · Cited by 3
Faisal, M. S., & Sung, P. J. (2023) · Leukemia Research Reports · doi:10.1016/j.lrr.2023.100386 · Cited by 3
Duployez, N., & Preudhomme, C. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.06.001 · Cited by 4
Genetic Mutations in Acute Myeloid Leukemia
Blau, O. (2016) · Clinical oncohematology · doi:10.21320/2500-2139-2016-9-3-245-256 · Cited by 3
Molecular Malfeasance Mediating Myeloid Malignancies: The Genetics of Acute Myeloid Leukemia
King, R. L., & Bagg, A. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7142-8_1 · Cited by 4
Zhu, M. Y., Zhu, Y., Chen, R., Zhu, L., Zhu, J., Li, X., Zhou, D., Yang, X., Zheng, Y., Xie, M., et al. (2020) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2020.02.003 · Cited by 3
Garay, C. M., Carrillo‐Sánchez, K., Flores‐Lagunes, L. L., Jiménez‐Olivares, M., Muñoz-Rivas, A., Villegas-Torres, B. E., Aguilar, H. F., Enríquez, J. C. N., Hernández, E. J., Méndez, V. C. B., et al. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.899742 · Cited by 3
“Biallelic mutation induces a biallelic expression of aberrant p30 isoforms; the residual p30 activity inhibits the remaining p42 protein in a dominant-negative manner and affects the myeloid differentiation process (27).”
BackgroundSingh, A., Upadhyay, V., Sethi, A., Chowdhury, S., Mishra, S., Verma, S., Bhatt, M. L. B., & Trivedi, A. K. (2024) · Biochemical Journal · doi:10.1042/bcj20240027 · Cited by 3
Germline Predisposition in Hematologic Malignancies
Kansal, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00126-8 · Cited by 3
Weinberg, O. K., & Arber, D. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-10940-9.00015-0 · Cited by 3
Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML
Fasan, A., Haferlach, C., Eder, C., Alpermann, T., Quante, A. S., Peters, A., Kern, W., Haferlach, T., & Schnittger, S. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2488-7 · Cited by 3
“These cases can be further characterized by different gene mutations including partial tandem duplication in the MLL gene [14, 39, 43], FLT3 tyrosine kinase mutations (FLT3-TKD) [2, 44], internal tandem duplications in FLT3 (FLT3-ITD) [40], NPM1 mutations [15, 41, 46], and CEBPA mutations [16, 31, 32].”
BackgroundSelf-citationNew Molecular Markers in Acute Myeloid Leukemia
de la Iglesia, S., Gómez‐Casares, M. T., Jorge, C. E. L., Lopez, J., & Martin, P. (2011) · InTech eBooks · doi:10.5772/27112 · Cited by 3
“CEBPA insertion, deletions and point mutations are detected usually by DNA sequencing (Wouters et al., 2009; Pabst et al., 2001; Fuchs et al., 2008).”
BackgroundGenetic abnormalities in acute myelogenous leukemia with normal cytogenetics
Wald, D. N., Vermaat, J. M., Peleg, G., & Tse, W. W. (2008) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-008-0013-y · Cited by 3
Zhao, J., Nana, N., Chang, L., Pengju, Z., Yu, Y., Zhaobo, C., Weiwen, C., & Anli, J. (2011) · AFRICAN JOURNAL OF BIOTECHNOLOGY · doi:10.5897/ajb11.088 · Cited by 3
“…promoter activity, whereas c/EBPα and p53 increases the promoter activity of pGL3-2123 about 3.6- fold and 2.0-fold, respectively. c/EBPα, one member of the c/EBP family, is a gene thought to be a tumor suppressor (Timchenko et al., 1996; Lekstrom-Himes and Xanthopoulos, 1998; Pabst et al., 2001).”
BackgroundInfluentialES02.01 Transcriptional regulation of haematopoiesis
Göttgens, B. (2004) · Vox Sanguinis · doi:10.1111/j.1741-6892.2004.00423.x · Cited by 3
Seifeddine, R., Fulchignoni‐Lataud, M., & Massaad-Massade, L. (2009) · PubMed · Cited by 3
Said, S. B., El-Masry, S. A., Salem, D., Taalab, M. M., & Al-posttany, A. S. (2015) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-015-0623-1 · Cited by 3
Molecular Diagnostics of Acute Myeloblastic Leukemia
Libura, M. A., Filip, A. A., & Haus, O. (2012) · Principles and practice · doi:10.1007/978-3-642-29467-9_24 · Cited by 3
“– Direct sequencing of the whole coding region (Pabst et al. 2001)”
Deshpande, A. J., Buske, C., Quintanilla‐Martínez, L., & Fend, F. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-5698-9_1 · Cited by 3
Myeloid differentiation and the leukemia-initiating cell
Tenen, D. G. (2014) · Leukemia Supplements · doi:10.1038/leusup.2014.14 · Cited by 2
Self-citationMolecular testing in acute myeloid leukemia
Behdad, A., & Betz, B. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822824-1.00019-5 · Cited by 2
Cancer Therapeutic Applications of Ribozymes and RNAi
Scherer, L. J., & Rossi, J. J. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-785-7_5 · Cited by 2
CEBPA dosage in leukemogenesis
Mercher, T., & Gilliland, D. G. (2006) · Blood · doi:10.1182/blood-2006-09-043059 · Cited by 2
Mixed T/myeloid phenotype acute leukemia with rare variants of IDH1 and CEBPA
Ma, Q., Tong, Y., Jin, J., & Lou, Y. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.783212 · Cited by 2
Staib, P., Lippl, S., & Spiekermann, K. (2015) · best practice onkologie · doi:10.1007/s11654-015-0247-9 · Cited by 4
Kimura, S., Paiz, J. A., Yoneda, M., Kido, T., Vinson, C., & Ward, J. M. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-90 · Cited by 2
“Further, specific somatic mutations are found in ~10% of acute myeloid leukemia (AML) patients [9,10].”
BackgroundSampath, D. (2012) · Springer eBooks · doi:10.1007/978-94-007-4655-8_7 · Cited by 2
Regulation of CCAAT/enhancer-binding protein (C/EBP) α in human-cytomegalovirus-infected fibroblasts
Lee, J., & Kim, S. (2016) · Archives of Virology · doi:10.1007/s00705-016-2768-0 · Cited by 2
CEBPA mutation in a case of chronic myeloid leukemia presenting in myeloid blast crisis
Yin, Y., Li, J., Yan, W., Cheng, Z., Sun, N., & Zhang, G. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1204655 · Cited by 2
Cytogenetic and Molecular Genetic Prognostic Factors of Acute Myeloid Leukemia
Misyurin, A. V. (2017) · Clinical oncohematology · doi:10.21320/2500-2139-2017-10-2-227-234 · Cited by 4
Cancer Genetics at a Glance: The Comprehensive Insights
Azarnezhad, A., & Mehdipour, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-64550-6_5 · Cited by 2
Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation
Radhakrishnan, S., Syed, R., Takei, H., Kobayashi, I. S., Nakamura, E., Sultana, F., Kamal, Ä., Tenen, D. G., & Kobayashi, S. S. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.06.024 · Cited by 2
Self-citationZeidner, J. F., Roy, D. B., Perl, A. E., & Gojo, I. (2018) · Wiley eBooks · doi:10.1002/9781118592168.ch29 · Cited by 3
Arber, D. A., & Heerema‐McKenney, A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7216-0040-6.00045-9 · Cited by 2
Kogan, S. C. (2004) · Wiley eBooks · doi:10.1002/0471675067.mmc013 · Cited by 2
Genomic Landscape and Risk Stratification of Acute Myeloid Leukemia
Hou, H. (2023) · Springer eBooks · doi:10.1007/978-981-99-3810-0_5 · Cited by 1
Adversarial attack of sequence-free enhancer prediction identifies chromatin architecture
Gafur, J., Lang, O. W., & Lai, W. (2025) · Bioinformatics · doi:10.1093/bioinformatics/btaf371 · Cited by 1
Stelzner, F. M. M., Schulz, A., Naß, N., Pannier, J., Kroll, H., & Behre, G. (2025) · Współczesna Onkologia · doi:10.5114/wo.2025.153783 · Cited by 1
Self-citationQu, F., Hui, M., Yang, F., Wan, W., Liu, N., Wu, X., He, Y., & Wang, X. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1775927 · Cited by 1
“…and dominant-negative effects, leading to a profound blockade in myeloid maturation and conferring a stem cell-like, self-renewal capacity to the leukemic clone, which forms the basis of the “differentiation arrest” phenotype in AML (Pabst et al., 2001; Reckzeh and Cammenga, 2010; Nerlov, 2004).”
Mannelli, F., Crupi, F., Bencini, S., Feuring‐Buske, M., Ciolli, G., Piccini, M., Frigeni, M., Palmieri, R., Sartor, C., Scappini, B., et al. (2026) · HemaSphere · doi:10.1002/hem3.70307 · Cited by 1
CEBP and ZEB2 alterations define three distinct subtypes of B‐cell acute lymphoblastic leukemia
Kim, R., Passet, M., Bergugnat, H., Vasseur, L., Leguay, T., Huguet, F., Hunault, M., Sexton, T., Benlebna, M., Renard, J., et al. (2026) · HemaSphere · doi:10.1002/hem3.70383 · Cited by 1
Lineage-Specific Transcription Factor Aberrations in AML
Mueller, B. U., & Pabst, T. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-69259-3_7 · Cited by 3
Self-citationTranscription Factors in Cancer Stem Cells of the Hematopoietic Lineage
Koschmieder, S., & Tenen, D. G. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-933-8_6 · Cited by 1
Self-citationMolecular Testing in Hematologic Malignancies
Behdad, A., Betz, B. L., Lim, M. S., & Bailey, N. G. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8050-2_10 · Cited by 1
Kern, W., Haferlach, T., Schnittger, S., Haferlach, C., & Bacher, U. (2010) · Wiley eBooks · doi:10.1002/9781444327359.ch9 · Cited by 1
Self-citationGodoy, P. R. D. V., S., S., S., F., В.А., Е., Passos, G. A. S., & T., E. (2013) · InTech eBooks · doi:10.5772/53299 · Cited by 1
“CEBPA is crucial for normal granulopoiesis, and dominant-negative mutations of CEBPA gene were found in patients with myeloblastic subtypes (M1 and M2) of acute myeloid leukemia [104].”
BackgroundA novel mutation in CEBPA gene in a patient with acute myeloid leukemia
Vinhas, R., Tolmatcheva, A., Canto, R., Ribeiro, P., Lourenço, A., de Sousa, A. B., Baptista, P. V., & Fernandes, A. R. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1065979 · Cited by 1
“have been identified in 7–15% of AML patients, correlating to a favorable clinical outcome [4,6].”
BackgroundAbsence of SCL mutations in myeloid malignancies
Delabesse, É., Li, J., Schnittger, S., Hiddemann, W., & Green, A. R. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04122.x · Cited by 1
“CEBPA plays a central role in granulocyte differentiation and acquired mutations have been found mainly in AML-M2, but also in AML-M1 and M4 (Pabst et al, 2001; Gombart et al, 2002).”
BackgroundSelf-citationCEBPA (CCAAT/enhancer binding protein (C/EBP), alpha)
Tian, T., & Graf, T. (2015) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/56435 · Cited by 2
Liao, Y.-C., & Chen, J.-H. (2012) · Tzu Chi Medical Journal · doi:10.1016/j.tcmj.2012.04.006 · Cited by 1
Management and orphan drug development for acute myeloid leukemia
Zhang, H., Li, S., & Li, H. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.891457 · Cited by 1
JAKed up phenotype of CEBPA-mutant AML
Tyner, J. W. (2016) · Blood · doi:10.1182/blood-2016-04-709535 · Cited by 1
Biology of Chronic and Acute Myeloid Leukemia
Quintás‐Cardama, A., Cortes, J. E., & Kantarjian, H. M. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10028-7 · Cited by 1
Application of the AMLprofiler Diagnostic Microarray in the South African Setting
Kappala, S. S., Alessandrini, M., Matlhako, T., Beltchev, E., Pool, R., & Pepper, M. S. (2017) · Stem Cells International · doi:10.1155/2017/2560191 · Cited by 1
El-Sharnouby, J. A., Ahmed, L. M. S., Taha, A. A., & Okasha, K. M. (2010) · Electronic Journal of General Medicine · doi:10.29333/ejgm/82788 · Cited by 1
“Platelet count, ×109/L Range (10-190) (20-310) 0.”
ResultArber, D. A. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3966-2.00043-6 · Cited by 1
Keeshan, K. (2021) · Blood · doi:10.1182/blood.2020008315 · Cited by 1
Zhang, J. P., Lin, D., Wang, S., Li, Y., Chen, Y. M., Wang, Y., Wei, H., Mi, Y., & Wang, J. X. (2020) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2020.12.007 · Cited by 1
Itzykson, R., Cerrano, M., & Esteve, J. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-72676-8_7 · Cited by 2
Chromosomal Translocations in Leukaemia: Emerging Networks
Bohlander, S. K. (2004) · Springer eBooks · doi:10.1007/978-94-017-1033-6_15 · Cited by 1
Heerema‐McKenney, A., & Arber, D. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2606-0.00014-7 · Cited by 1
Hu, Z., Liu, Y., Yao, Z., Chen, L., Wang, G., Liu, X., Tian, Y., & Cao, G. (2022) · Hereditas · doi:10.1186/s41065-022-00261-w · Cited by 1
Diagnosis of pediatric acute myeloid leukemia and mixed-phenotype acute leukemia
Parisi, X., & Bledsoe, J. R. (2025) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2025.07.001 · Cited by 1
FLT3, NPM1 y C/EBPα as prognosis markers in patients with acute myeloid leukemia
Lagunas‐Rangel, F. A., Pérez-Contreras, V. A., & Cortés‐Penagos, C. (2015) · Revista de Hematología · Cited by 1
Molecular Markers for Risk Stratification in Adult Acute Myeloid Leukemia with Normal Cytogenetics
Fuchs, O. (2011) · InTech eBooks · doi:10.5772/19844 · Cited by 2
“transactivation by C/EBPα p42 (Pabst et al., 2001).”
BackgroundTranscriptional Repression of C/EBPα by Histone Deacetylases in Acute Myeloid Leukemia
Steffen, B., Ruthardt, M., Becker, K., Klümpen, S., Möller, M., Berdel, W. E., Serve, H. L., & Müller‐Tidow, C. (2003) · Hämatologie und Bluttransfusion · doi:10.1007/978-3-642-59358-1_10 · Cited by 1
Kowenz‐Leutz, E., Schuetz, A., Liu, Q., Knoblich, M., Heinemann, U., & Leutz, A. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.04.008 · Cited by 3
Molecular Biology of Leukemias
Medeiros, L. J., & Konoplev, S. N. (2016) · Springer eBooks · doi:10.1007/978-1-59745-458-2_30 · Cited by 1
GENOMIC MICROARRAYS IN CHROMOSOMAL ANALYSIS OF LEUKEMIA
Tyybäkinoja, A. (2009) · Työväentutkimus Vuosikirja · Cited by 1
A genome-wide survey of alternative translational initiation events in Homo sapiens
Zhang, J., Cai, J., & Li, Y. (2007) · Science in China Series C Life Sciences · doi:10.1007/s11427-007-0040-2 · Cited by 1
Mutations in human cancer: how close should we look?
Cammenga, J., & Nimer, S. D. (2002) · Leukemia Research · doi:10.1016/s0145-2126(01)00174-6 · Cited by 1
ABERRANT EPIGENETICS IN THE MOLECULAR PATHOGENESIS OF HUMAN ACUTE MYELOID LEUKEMIA
Scott, S. A. (2005) · University Library - University of Saskatchewan (University of Saskatchewan) · Cited by 1
Advances in Molecular Cytogenetics to Study the Leukemia Genome
Strefford, J. C., & Harrison, C. J. (2007) · Laboratory Medicine · doi:10.1309/jl7fk85ebgmwh4fl · Cited by 1
C/EBP transcription factors in lung cellular differentiation and development
Berg, T. (2005) · Figshare · Cited by 1
Acute lymphoblastic leukemia (ALL)
Paz‐Priel, I., & Friedman, A. D. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.072 · Cited by 1
Molecular mechanisms and gene expression patterns in myelodysplastic syndromes
Hofmann, W., & Koeffler, H. P. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511545269.006 · Cited by 1
Techniques to Determine Clonality in Hematolymphoid Malignancies
Sabath, D. E. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-5698-9_8 · Cited by 1
Elenitoba‐Johnson, K. S. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6164-9.00044-5 · Cited by 1
Metadata
- Authors
- Pabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G.
- Affiliations
- Harvard University (US)
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Tenen, Daniel G.
- Venue
- Nature Genetics
- Published
- 2001-03
- Volume
- 27
- Issue
- 3
- Pages
- 263-270
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2100088478
- Cited by
- 901
- References
- 33
- Citations by year
- 2026: 15 · 2025: 11 · 2024: 23 · 2023: 21 · 2022: 30 · 2021: 22 · 2020: 27 · 2019: 17 · 2018: 22 · 2017: 27 · 2016: 29 · 2015: 47 · 2014: 37 · 2013: 34 · 2012: 50
- FWCI
- 23.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL056745, HL56745)
- National Cancer Institute (CA-72009, P01CA072009)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- CEBPA, C/EBPα, acute myeloid leukemia, dominant negative mutation, heterozygous mutation, transcription factors, granulocytic differentiation, DNA binding, transcriptional activation, N-terminal truncation
- MeSH terms
- Base Sequence, Cell Differentiation, Cell Nucleus, DNA, Neoplasm, Genes, Dominant, Granulocytes, Heterozygote, Humans, Mutation, Neutrophils, Leukemia, Myeloid, Acute, Transcriptional Activation, Sequence Deletion, DNA Primers, CCAAT-Enhancer-Binding Protein-alpha, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.